Empagliflozin and Cardiac Remodelling in People Without Diabetes
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of empagliflozin on cardiac structure,
function and circulating biomarkers in patients with cardiovascular risk factors, but without
diabetes. Empagliflozin is an antihyperglycemic agent approved by Health Canada and the FDA
for the treatment of type 2 diabetes. Previous post-marketing clinical trials demonstrated a
reduction in cardiovascular deaths and heart failure in patients with type 2 diabetes treated
with empagliflozin. In the first EMPA-HEART trial, we demonstrated that empagliflozin reduces
cardiac mass in patients with type 2 diabetes, as seen through cardiac magnetic resonance
imaging (cMRI). Therefore, the aim of this study, EMPA-HEART 2, is to determine whether
empagliflozin can similarly impact cardiac structure in patients without diabetes, but with
various cardiovascular risk factors.
Phase:
Phase 4
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto
Collaborators:
Applied Health Research Centre Boehringer Ingelheim Canadian Medical and Surgical Knowledge Translation Research Group